News

Apr 22, 2020

Slenyto (PedPRM) is now available in France!

Feb 11, 2020

Slenyto (PedPRM) is now available in Denmark!

Jan 27, 2020

Slenyto (PedPRM) is now also available in Iceland!

Jan 14, 2020

Slenyto (PedPRM) is now available in Switzerland!

Sep 18, 2019

Slenyto (PedPRM) is now available in Norway!

Jun 27, 2019

Neurim Pharmaceuticals attends the ESCAP Congress in Vienna, Austria, 30 June – 2 July 2019

May 23, 2019

Slenyto (PedPRM) is now also available in Italy!

Apr 8, 2019

Neurim Pharmaceuticals attends the EPA Congress in Warsaw, Poland, April 7-9, 2019

Apr 3, 2019

Slenyto (PedPRM) is now also available in UK!

Apr 1, 2019

Slenyto is now available in Finland

Jan 27, 2019

Slenyto is now available in Germany

Nov 5, 2018

Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient

Jul 30, 2018

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD) (Read more)

May 7, 2018

Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018

Apr 16, 2018

Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.

Jan 17, 2018

Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland (Read more)

Dec 19, 2017

Circadin is celebrating 10 years in market!

Oct 15, 2017

Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague (Read more)

Sep 25, 2017

Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland (Read more)

Sep 24, 2017

Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th